Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
(May 9th, 2025) Biomay announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications.
Clients purchasing Biomay’s Cas9 will benefit from the company’s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease …
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease
(April 28th, 2025) Biomay announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals …
> More info